FibroGen Inc (FGEN)
0.304
-0.02
(-5.68%)
USD |
NASDAQ |
Nov 05, 16:00
0.304
0.00 (0.00%)
After-Hours: 16:27
FibroGen Gross Profit Margin (Quarterly): 89.78% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 89.78% |
| March 31, 2024 | 53.93% |
| December 31, 2023 | 80.08% |
| September 30, 2023 | 89.43% |
| June 30, 2023 | 87.12% |
| March 31, 2023 | 90.35% |
| December 31, 2022 | 85.67% |
| September 30, 2022 | 72.62% |
| June 30, 2022 | 77.16% |
| March 31, 2022 | 93.03% |
| Date | Value |
|---|---|
| December 31, 2021 | 81.11% |
| September 30, 2021 | 97.91% |
| June 30, 2021 | 87.37% |
| March 31, 2021 | 91.15% |
| December 31, 2020 | 95.98% |
| September 30, 2020 | 94.99% |
| June 30, 2020 | 92.83% |
| March 31, 2020 | 96.02% |
| December 31, 2019 | 88.65% |
| September 30, 2019 | 99.27% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
53.93%
Minimum
Mar 2024
97.91%
Maximum
Sep 2021
86.59%
Average
89.43%
Median
Sep 2023
Gross Profit Margin (Quarterly) Benchmarks
| Merck & Co Inc | 75.51% |
| Biomarin Pharmaceutical Inc | 74.73% |
| Arbutus Biopharma Corp | -- |
| GlycoMimetics Inc | -- |
| Cidara Therapeutics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -40.89% |
| Profit Margin (Quarterly) | -30.69% |
| Operating Margin (Quarterly) | -21.56% |
| Return on Net Operating Assets | -81.57% |